WHO

For biopharma and big pharma leaders across the Nordics - from R&D, MSAT, and manufacturing to digital, quality, and strategic teams who are advancing the next generation of biologics. This summit unites R&D, clinical development, Quality Assurance (QA), Manufacturing Science and Technology (MSAT), and manufacturing functions from leading pharmaceutical companies and emerging biotechs.

WHAT

A strategic platform designed to bridge the Nordics' strong biologics R&D capabilities with scalable GMP manufacturing. The summit features two concurrent tracks:

R&D & Clinical Trials and Biologics Manufacturing - offering targeted insights across the full development and production spectrum.

Key themes driving every session include:

• R&D Innovation & Clinical-to-GMP Translation
• Biologics Manufacturing & Scale-Up
• Digitalisation, Automation & Quality
• Strategic & Public-Private Partnerships

Built around the Nordics’ strengths, the event connects academic, clinical, and commercial stakeholders to drive the full lifecycle of biologics from discovery to commercialisation.

WHY

To enable end-to-end collaboration by uniting R&D, clinical development, and manufacturing functions across the entire biologics value chain. The summit aligns these functions through shared challenges, practical insight, and country-specific case studies.

Whether you are focused on achieving scalable production , developing regional infrastructure , or integrating digital technologies like AI and GMP 4.0 , this is where Nordic science meets global strategy.